Hua Yingjie, Sun Xuehui, Luan Kefeng, Wang Changlei
Department of Stomatology, Affiliated Hospital of Weifang Medical University, 2428 Yuhe Road, Kuiwen District, Weifang City, Shandong Province, 261041, China.
Open Life Sci. 2022 Sep 14;17(1):1135-1147. doi: 10.1515/biol-2022-0467. eCollection 2022.
Oral squamous cell carcinoma (OSCC) prognosis remains poor. Here we aimed to identify an effective prognostic signature for predicting the survival of patients with OSCC. Gene-expression and clinical data were obtained from the Cancer Genome Atlas database. Immune microenvironment-associated genes were identified using bioinformatics. Subtype and risk-score analyses were performed for these genes. Kaplan-Meier analysis and immune cell infiltration level were explored in different subtypes and risk-score groups. The prognostic ability, independent prognosis, and clinical features of the risk score were assessed. Furthermore, immunotherapy response based on the risk score was explored. Finally, a conjoint analysis of the subtype and risk-score groups was performed to determine the best prognostic combination. We found 11 potential prognostic genes and constructed a risk-score model. The subtype cluster 2 and a high-risk group showed the worst overall survival; differences in survival status might be due to the different immune cell infiltration levels. The risk score showed good performance, independent prognostic value, and valuable clinical application. Higher risk scores showed higher Tumor Immune Dysfunction and Exclusion scores, indicating that patients with a high-risk score were less likely to benefit from immunotherapy. Finally, conjoint analysis for the subgroups and risk groups showed the best predictive ability.
口腔鳞状细胞癌(OSCC)的预后仍然很差。在此,我们旨在确定一种有效的预后特征,以预测OSCC患者的生存率。基因表达和临床数据来自癌症基因组图谱数据库。使用生物信息学鉴定免疫微环境相关基因。对这些基因进行亚型和风险评分分析。在不同亚型和风险评分组中进行Kaplan-Meier分析和免疫细胞浸润水平研究。评估风险评分的预后能力、独立预后价值和临床特征。此外,还探讨了基于风险评分的免疫治疗反应。最后,对亚型和风险评分组进行联合分析,以确定最佳预后组合。我们发现了11个潜在的预后基因,并构建了一个风险评分模型。亚型聚类2和高危组的总生存期最差;生存状态的差异可能归因于不同的免疫细胞浸润水平。风险评分显示出良好的性能、独立的预后价值和有价值的临床应用。较高的风险评分显示出较高的肿瘤免疫功能障碍和排除评分,表明高危评分患者从免疫治疗中获益的可能性较小。最后,对亚组和风险组的联合分析显示出最佳的预测能力。